Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023
Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023
Read also
Three scientists win Nobel Prize
Three scientists win Nobel Prize in chemistry for creating new molecular structure
Boehringer
Boehringer bags FDA okay for new pulmonary fibrosis drug
Editas Medicine reports 90% LDL-C reduction in preclinical studies
CAMBRIDGE, Mass. - Editas Medicine, Inc., whose stock has surged over 260% in the past six months according to InvestingPro data
China accounts for one-fifth of global drugs in development
China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in the pharmaceutical industry.
